BBIO
BridgeBio Pharma, Inc. Common Stock
After-Market
70.25
BridgeBio Pharma, Inc. Common Stock Profile
About
Info & Links
CEO
Neil Kumar
Headquarters
PALO ALTO, CA 94304, UNITED STATES
Industry
Sector
Website
Auditor
Deloitte & Touche LLP
Share holders
34
Employees
839
BridgeBio Pharma, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
13.73B
Enterprise Value
15.53B
Enterprise Value/EBITDA(ttm)
-31.95
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
19.88
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
94.51%
Operating Margin(ttm)
-97.03%
Profit Margin(ttm)
-105.82%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
420.60%
Return on Assets(ttm)
-61.19%
Income Statement
Revenue(ttm)
713.07M
Revenue Per Share(ttm)
3.65
Gross Profit(ttm)
673.41M
EBITDA(ttm)3
-486.07M
Net Income Available to Common(ttm)
-691.87M
Diluted EPS(ttm)
-3.57
Share Statistics
Beta (5Y Monthly)
0.97
52-Week Change
36.78%
S&P 500 52-Week Change
18.73%
S&P 500 Member
No
Stock Optionable
Yes
Total Shares Outstanding1
195.49M
Dividend Yield
0.00%
Float4
167.67M
% Held by Insiders
14.23%
% Held by Institutions
99.85%
Balance Sheet
Total Cash(mrq)
720.16M
Total Cash Per Share(mrq)
3.68
Total Debt(mrq)
2.48B
Total Debt/Equity(mrq)
-98.83%
Current Ratio(mrq)
1.23%
Quick Ratio(mrq)
1.17%
Book Value Per Share(mrq)
-12.83
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.37
Free Cash Flow(ytd)
-268.89M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.